Dr. Doebele is a pioneer physician-scientist and board-certified medical oncologist who lives and breathes new biology-based, tumor-agnostic strategies to offer hope. Dr. Doebele has expansive clinical and research expertise in targeted therapies and precision oncologystrategies having led research at the University of Colorado that launched the TRK field by demonstrating that that NTRK1/2/3 gene fusions represent a novel tumor agnostic target in cancer, a strategy that ultimately led to the approval of larotrectinib (Loxo) and entrectinib (Ignyta). Prior to joining Rain full time, Dr. Doebele was an associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine. He also served as the director of the thoracic oncology research initiative at the University of Colorado Cancer Center; and was the principal investigator of the University of Colorado Lung Cancer Specialized Program of Research Excellence. He is also a senior editor of the AACR journal, Clinical Cancer Research. Dr. Doebele received his AB in molecular biology from Princeton University, and received his MD, PhD in immunology from the University of Pennsylvania. He conducted his internal medicine residency and a medical oncology fellowship at the University of Chicago.
Dr. Kunkel currently serves on the board of directors of Loxo Oncology, Inc., Curis, Inc., Maverick Therapeutics, Inc. and Tocagen, Inc. Previously she has served as acting chief medical officer of Loxo Oncology, Inc., Pharmacyclics, LLC and Proteolix, Inc. and vice president of clinical development at Xencor, Inc. Prior to her career in biotechnology, Lori spent a decade in academic medicine as a faculty member at the bone marrow transplant unit in the division of hematology/oncology at University of California, Los Angeles. Lori has held board certifications in hematology and oncology and holds a BA in biology from the University of California, San Diego and an MD from the University of Southern California.
Dr. Kirk is cofounder, president and chief scientific officer of Kezar Life Sciences. Dr. Kirk has worked in the biotechnology industry since 2001 and has held numerous positions in drug discovery and development. Prior to forming Kezar, Dr. Kirk was the vice president of research at Onyx Pharmaceuticals, where he played a key role in the discovery and development of two proteasome inhibitors, carfilzomib (KYPROLIS™) and oprozomib. Dr. Kirk joined Onyx via the acquisition of Proteolix in 2009, where he was one of the first scientific hires after their Series A funding. Dr. Kirk received his BS from U.C. Davis and his PhD in cellular and molecular biology from the University of Michigan in 1999.
Dr. Bivona is a professor in residence and an attending physician in thoracic oncology at UCSF, and serves on the advisory boards for AstraZeneca, Novartis, Array Biopharma, Revolution Medicines, Inventiva, Takeda and Jazz Pharmaceuticals. As a physician-scientist with training in medical oncology and a PhD in cell and molecular biology, he directs a laboratory-based research program in basic and translational oncology at UCSF. He has successfully translated six laboratory-based discoveries into clinical trials over the last eight years in the form of investigator-initiated (6) and company-sponsored (2) clinical studies. His areas of interest include cancer, lung, kinases, oncogenes, tyrosine kinase inhibitors, genomics and signal transduction. Dr. Bivona has served as an ad hoc reviewer for over 20 professional publications and has supervised/mentored a multitude of predoctoral students, postdoctoral fellows/residents and faculty members. Dr. Bivona received his BS with honors in molecular biology at Vanderbilt University, his PhD in molecular and cell biology at NYU School of Medicine in 2004 and his MD at NYU School of Medicine in 2005. He was a clinical fellow at Harvard, a fellow of oncology at Memorial Sloan-Kettering and postdoctoral fellow at Memorial Sloan-Kettering. He is board certified in internal medicine and medical oncology.
Dr. Powell is the Enid A. Haupt professor and chairman of the Department of Radiation Oncology at the Memorial Sloan Kettering Cancer Center. He is also a member of the Molecular Biology Program of the Sloan-Kettering Institute, and Weill Cornell Graduate School of Medical Sciences. His primary interests are DNA repair, breast cancer, cancer specific defects in DNA repair and the DNA damage response pathway. Dr. Powell has deep expertise specifically on the role of RAD52 in mediating the DNA damage response pathway, where his lab is one of the leading research centers in the field, and Dr. Powell has co-authored several peer-reviewed publications elucidating the potential of RAD52 as a therapeutic target for cancers characterized by BRCA1/2 deficiencies. Through this work, Dr. Powell contributed to the discovery of synthetic lethality in cancer cells lacking the function of the BRCA1-BRCA2 pathway, which has both mechanistic implications as well as applications for therapeutic strategies. Dr. Powell was an undergraduate at Oxford University and received his doctoral training in both medicine and science from the University of London.